Ultomiris Shows Promise in IgA Nephropathy: What the Phase III I CAN Trial Reveals

The race to slow kidney disease progression just got more interesting. Ultomiris has delivered positive interim results in a Phase III trial for immunoglobulin A nephropathy (IgAN). The takeaway: a meaningful reduction in proteinuria, a key marker of kidney damage.

But before calling this a breakthrough, let’s break down what actually matters.

The Headline Result (And Why It Matters)

At week 34, Ultomiris hit its primary endpoint:

• Statistically significant reduction in proteinuria (measured via UPCR)
• Clinically meaningful impact, not just a marginal win
• Early effect seen as soon as week 10

This matters because:

• Proteinuria is a validated surrogate marker in IgAN
• Lower protein levels often correlate with slower disease progression
• It gives regulators a basis for accelerated approval discussions

What’s still pending?

• The second primary endpoint: change in eGFR at week 106
• Translation: we don’t yet know if this actually preserves kidney function long-term

IgA Nephropathy: A Silent Progressor

Immunoglobulin A Nephropathy isn’t just rare, it’s deceptive.

What’s happening biologically:

• Abnormal IgA proteins form immune complexes
• These deposit in the kidneys
• They trigger the complement system
• Result: chronic inflammation → structural damage

Why it’s dangerous?

• Often asymptomatic early on
• Diagnosed late, when damage is already irreversible
• ~50% of high-risk patients progress to kidney failure within 10 years

Common signs (when they appear):

• Blood in urine (haematuria)
• Foamy urine (proteinuria)
• Swelling (oedema)
• High blood pressure

The problem? By the time these show up, the disease has already done its damage.

The Mechanism Bet: Targeting Complement Activation

Ultomiris isn’t treating symptoms—it’s targeting the engine. It works by inhibiting C5 in the complement cascade, which:

• Prevents terminal complement activation
• Reduces inflammation in kidney tissue
• Potentially slows structural damage

This is the same biological pathway that’s already proven in:

• Paroxysmal Nocturnal Hemoglobinuria
• Atypical Hemolytic Uremic Syndrome

Now the question is: Will that success translate to IgAN?

Inside the I CAN Phase III Trial

This isn’t a small, exploratory study.

Trial Design Snapshot:

• Name: I CAN (ALXN1210-IgAN-320)
• Type: Randomized, double-blind, placebo-controlled
• Participants: ~510 patients
• Geography: 28 countries
• Duration: 106 weeks

Treatment Protocol:

• Loading dose on Day 1
• Maintenance dosing every 8 weeks
• Patients stayed on standard of care therapies

Primary Endpoints:

• Proteinuria reduction at week 34 (✔ achieved)
• eGFR change at week 106 (⏳ pending)

Key Secondary Measures:

• ≥50% reduction in proteinuria
• Time to 30% eGFR decline
• Composite kidney events

This design signals something important: The company is aiming for disease-modifying evidence, not just symptomatic relief.

What Leadership Is Saying (And What It Implies)

Jonathan Barratt highlights the unmet need:

• Patients still progress to dialysis or transplant
• Current treatments aren’t enough to halt disease

Marc Dunoyer frames the strategy:

• Rapid proteinuria reduction supports early intervention potential
• Plans to pursue accelerated regulatory filings

Translation:

• The company is betting on surrogate endpoints to move faster
• But long-term kidney protection remains the real proof point

Safety: No Surprises (So Far)

The safety profile was:

• Consistent with existing data
• No new safety concerns identified

That’s expected. Ultomiris is already approved across multiple indications, including:

• Generalized Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder

This reduces regulatory friction—but doesn’t eliminate scrutiny in a new disease setting.

Market Context: Why This Matters Commercially

The patient pool isn’t trivial:

• 560,000+ diagnosed patients across US, EU5, Japan
• 60% eligible for treatment

Combine that with:

• Chronic disease progression
• Limited disease-modifying therapies
• High cost burden of dialysis/transplant

You get a high-value rare disease market with scale

The Devil’s Advocate Take

Let’s stress-test the narrative.

1. Proteinuria ≠ Long-Term Outcomes (Yet)

• Regulators may accept it for acceleration
• But eGFR data will decide real value

2. Complement Inhibition Is Expensive

• Will pricing limit adoption?
• Especially outside premium markets?

3. Competitive Landscape Is Heating Up

• Multiple mechanisms are being explored
• Not all roads lead through complement

4. IV Administration Is a Constraint

• Every 8 weeks is convenient—for IV
• But still less flexible than oral therapies

What to Watch Next?

The next 12–24 months will define everything:

• Final eGFR data at week 106
• Regulatory filings and approvals
• Real-world adoption dynamics
• Competitive trial readouts

Bottom Line

Ultomiris has cleared an important early hurdle in IgAN. But this is still a “promising, not proven” story. If the eGFR data confirms disease modification, this could reshape treatment.
If not, it risks becoming another incremental improvement dressed as innovation. Either way, the complement pathway is now firmly in play.